-
Demographics (3 min.)
-
Basics about AVP-Deficiency (5 min)
-
Patient Education (5 min)
-
Diagnosis and Outpatient Treatment Decisions (5 min)
-
Hospital Care Decisions (5 min)
In 2022, the Endocrine Society and the global ‘Working Group for Renaming Diabetes Insipidus recommended a name change from diabetes insipidus (CDI) to Arginine Vasopressin Deficiency (AVP-Deficiency, AVP-D) in order to better reflect the condition’s pathophysiology and avoid confusion with diabetes mellitus. But has this change been widely adopted in clinical practice? Is there still confusion between the two terms in 2025? Do healthcare professionals and patients understand how to safely manage AVP-D and desmopressin (and avoid complications like hyponatremia and hypernatremia)?
We wish to gather insights on how AVP-Deficiency is understood, diagnosed, and managed across specialties (both endocrine and non-endocrine). Your participation will help improve patient education and clinical practices for this rare condition. The survey takes just a few minutes, and your responses are anonymous. Your time and effort is greatly appreciated: by answering our survey you will be helping us to improve AVP-D awareness and patient safety!
Christine Yedinak M.N., F.N.P., D.N.P. from the Oregon Health Sciences University Pituitary Center
Pat Gildroy, Ph.D. Lead Administrator
Muriël Marks, Executive Director
© 2025, J D Faccinetti. All rights reserved.